Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?

ESMO Open. 2024 May;9(5):102990. doi: 10.1016/j.esmoop.2024.102990. Epub 2024 Apr 24.

Authors

S Sammons¹, N U Lin²

Affiliations

¹ Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
² Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA. Electronic address: Nancy_Lin@dfci.harvard.edu.

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use
Brain Neoplasms* / drug therapy
Brain Neoplasms* / secondary
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Humans
Immunoconjugates* / pharmacology
Immunoconjugates* / therapeutic use
Receptor, ErbB-2* / metabolism

Substances

Immunoconjugates
Receptor, ErbB-2
ERBB2 protein, human
Antineoplastic Agents, Immunological